{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Mohamed Abdel-Fattah, David Cooper, Tracey Davidson, Mary Kilonzo, Dwayne Boyers, Kiron Bhal, Alison McDonald, Judith Wardle, James N’Dow, Graeme MacLennan & John Norrie.

Mohamed Abdel-Fattah ^1,*, David Cooper ², Tracey Davidson ², Mary Kilonzo ³, Dwayne Boyers ³, Kiron Bhal ⁴, Alison McDonald ¹, Judith Wardle ⁵, James N’Dow ⁶, Graeme MacLennan ¹, John Norrie ⁷

¹ Aberdeen Centre For Women’s Health Research, University of Aberdeen, Aberdeen, UK
² Health Services Research Unit, University of Aberdeen, Aberdeen, UK
³ Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
⁴ Obstetrics and Gynaecology, University Hospital of Wales, Cardiff, UK
⁵ Patient and public involvement lead, , UK
⁶ Academic Urology Unit, University of Aberdeen, Aberdeen, UK
⁷ Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK
^* Corresponding author Email: m.abdelfattah@abdn.ac.uk

Declared competing interests of authors: Graeme MacLennan reports grants from the National Institute for Health and Care Research (NIHR) during the conduct of the study. John Norrie reports grants from the University of Edinburgh, outside the submitted work. He also reports past and present membership of the following: HTA Commissioning Sub-Board (Expression of Interest) (2014–16), NIHR Clinical Trials Unit Standing Advisory Committee (2016–22), NIHR Health Technology Assessment (HTA) and Efficacy and Mechanism Evaluation (EME) Editorial Boards (2013–19), Pre-Exposure Prophylaxis Impact Review Panel (2017–20), EME Strategy Advisory Committee (2019 to present), EME – Funding Committee Members (2019 to present), EME Funding Committee Sub-Group Remit and Comp Check (2019 to present), HTA General Committee (2016–19), HTA Funding Committee Policy Group (formerly Clinical Studies Group) (2016–19), HTA Commissioning Committee (2010–16), HTA Post-funding committee teleconference (2016–19) and COVID-19 reviewing (2020). James N’Dow reports membership of the HTA General Committee (2016–18). Mohamed Abdel-Fattah reports membership of the HTA IP Panel (2014–18). Before 2015, he was a speaker, consultant and/or surgical trainer for a number of industrial companies [Astellas Pharma Inc. (Tokyo, Japan); Ethicon, Inc. (Bridgewater, NJ, and Cincinnati, OH, USA); Bard Pharmaceuticals Ltd (Cambridge, UK); Pfizer Inc. (New York, NY, USA); American Medical Systems, Inc. (Minnetonka, MN, USA); Coloplast A/S (Humlebæk, Denmark); and others]; he was reimbursed travel expenses and, on occasion, received personal honorariums, proctorship fees and sponsorship towards attending scientific conferences. He received a research grant from Coloplast managed by the University of Aberdeen. A limited number of his trainees attended pharmaceutical-sponsored educational/leadership workshops and/or received assistance towards presenting their research work in scientific conferences. He was Chairman of the Scottish Pelvic Floor Network (SPFN), which, at the time, received financial sponsorship from various industrial companies (including all those mentioned previously) and non-profit organisations for its annual meetings and surgical workshops. The SPFN provided an educational grant funding the principal investigator at the highest-recruiting site to attend the International Continence Society annual scientific conference in Brazil in 2014. He receives travel sponsorship and occasionally speaker’s fees from numerous national and international conferences and non-profit organisations when invited as guest speaker and/or expert surgeon. In 2019, and at request from NHS Grampian, he attended two educational meetings for setting up a sacral nerve stimulation service partially funded by Medtronic plc (Dublin, Ireland). He is chief investigator for four NIHR HTA-funded studies. He does not hold (and never held) any shares (or similar) in any of the industrial companies (medical or non-medical). To the best of his knowledge, none of the above has influenced his research or clinical practice.